Cover Image
市場調查報告書

生物學的安全性檢驗的全球市場 2019年:幹細胞·血液·基因治療

Biological Safety Testing Market by Application (Stem Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), Test (Bioburden, Endotoxin, Cell Line Authentication, Residual Contamination, Adventitious Agents): Global Forecast - 2019

出版商 MarketsandMarkets 商品編碼 328907
出版日期 內容資訊 英文 182 Pages
訂單完成後即時交付
價格
Back to Top
生物學的安全性檢驗的全球市場 2019年:幹細胞·血液·基因治療 Biological Safety Testing Market by Application (Stem Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), Test (Bioburden, Endotoxin, Cell Line Authentication, Residual Contamination, Adventitious Agents): Global Forecast - 2019
出版日期: 2015年04月21日 內容資訊: 英文 182 Pages
簡介

全球生物學的安全性檢驗市場預計從2014年到2019年將以12.23%的年複合成長率成長,到2019年達到17億5869萬美元的規模。

本報告提供全球生物學的安全性檢驗市場相關調查分析,提供您產品,實驗種類,用途及地區別分析·預測,並彙整競爭情形分析,主要企業簡介等資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 在全球生物學的安全性檢驗市場上獲得利益的機會
  • 生命週期分析:各地區

第5章 市場概要

  • 簡介
  • 市場區隔
    • 各應用領域
    • 各產品
    • 檢查別
  • 市場動態
    • 促進要素
    • 阻礙要素
    • 機會
    • 課題

第6章 產業趨勢

  • 簡介
  • 波特的五力分析
  • 策略性基準
  • 供應鏈分析

第7章 生物學的安全性檢驗市場:各用途

  • 簡介
  • 疫苗·治療
  • 血液·血液製劑
  • 細胞·基因治療產品
  • 細胞·細胞產品
  • 幹細胞產品

第8章 生物學的安全性檢驗市場:各產品

  • 簡介
  • 套件 & 試劑
  • 服務
  • 器具

第9章 生物學的安全性檢驗市場:檢查別

  • 簡介
  • 內毒素檢驗
  • 無菌檢查
  • 細胞株認證·特性化實驗
  • 微生物負荷實驗
  • 殘留的宿主污染物檢測實驗
  • 偶發性化學物質檢測實驗
  • 其他實驗

第10章 地區分析

  • 簡介
  • 北美
  • 歐洲
  • 亞洲
  • 其他

第11章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形 & 趨勢

第12章 企業簡介

  • 簡介
  • Charles River Laboratories International, Inc.
  • Lonza Group
  • Sigma-Aldrich Corporation
  • SGS S.A.
  • Wuxi Pharmatech (Cayman) Inc.
  • Avance Biosciences Inc.
  • Bsl Bioservice
  • Cytovance Biologics, Inc.
  • Merck & Co., Inc.
  • Toxikon Corporation

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 3334

The biologics safety testing market is growing at a favorable rate. The major drivers for the market include growth of the pharmaceutical and biological industries and an increasing number of new drug launches. Over the years, the number of drug approvals in North American countries has increased. Between 2001 and 2010, the FDA approved 225 drug applications and Health Canada approved 99. In addition, according to WIPO, Europe accounted for 3,822 of the pharmaceutical and 1,998 of the biotechnology patents granted in 2012. Furthermore, according to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970. This will spur the growth of biologics safety testing market.

The global pharmaceutical industry is expected to grow at a CAGR between 5% and 8%. According to the IMS Institute of Healthcare Informatics, the global biologics market has increased from $46 billion in 2002 to $169 billion in 2012. Biologics accounted for 11% of the total sales of drugs in 2002, which increased to 18% in 2012. It is estimated that this figure will rise to 20% by 2017, with a total market value of $221 billion. According to Ernst & Young's Global Biotechnology Report 2013, companies in biotech centers in the U.S., Europe, Canada, and Australia achieved revenues of about $90 billion in 2012. This was an 8% increase over their revenues in 2011. According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Biologics safety testing is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the biologics safety testing market.

This report segments the global biologic safety testing market based on product, type of test, application, and geography. The product segments included in the report are instruments, kits & reagents, and services. Based on test, this market is categorized into adventitious agents detection test, bioburden tests, cell line authentication and characterization tests, endotoxin tests, residual host contaminant detection tests, sterility testing, and other tests (efficacy tests, toxicity tests, stability tests). The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissues & tissue products, and vaccines and therapeutics.

The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). Asia is further divided into China, India, Japan, and the Rest of Asia. North America includes Canada and the U.S.

A combination of bottom-up and top-down approaches were used to calculate market sizes and growth rates of the global biologics safety testing market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of their biologics safety testing market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and the growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the biologic safety testing market. The competitive landscape covers growth strategies adopted by industry players over the last three years, and includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

  • Product Development/Innovation: Product portfolios of top players in the biologic safety testing market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the biologic safety testing market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the biologic safety testing market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biologics safety testing products across geographies
  • Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the biologics safety testing market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOLOGICS SAFETY TESTING MARKET
  • 4.2. LIFE CYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY APPLICATION
    • 5.2.2. BY PRODUCT
    • 5.2.3. BY TEST
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Rapid growth in pharmaceutical and biotechnology industries
      • 5.3.1.2. Increasing number of new drug launches
      • 5.3.1.3. Strong trend of R&D investments in life sciences
      • 5.3.1.4. Increasing government support for pharmaceutical and biotechnology industries
      • 5.3.1.5. High incidence and large economic burden of chronic diseases
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. High degree of consolidation acts as an entry barrier for new entrants
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Increasing pharmaceutical outsourcing
      • 5.3.3.2. Developing countries
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Stringent regulatory frameworks and time-consuming approval processes

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. PORTER'S FIVE FORCES ANALYSIS
    • 6.2.1. THREAT OF NEW ENTRANTS
    • 6.2.2. THREAT OF SUBSTITUTES
    • 6.2.3. BARGAINING POWER OF BUYERS
    • 6.2.4. BARGAINING POWER OF SUPPLIERS
    • 6.2.5. INTENSITY OF RIVALRY
  • 6.3. STRATEGIC BENCHMARKING
    • 6.3.1. EXPANSIONS AND ACQUISITIONS
  • 6.4. SUPPLY CHAIN ANALYSIS
    • 6.4.1. KEY INFLUENCERS

7. BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. VACCINES AND THERAPEUTICS
  • 7.3. BLOOD AND BLOOD PRODUCTS
  • 7.4. CELLULAR AND GENE THERAPY PRODUCTS
  • 7.5. TISSUE AND TISSUE PRODUCTS
  • 7.6. STEM CELL PRODUCTS

8. BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT

  • 8.1. INTRODUCTION
  • 8.2. KITS & REAGENTS
  • 8.3. SERVICES
  • 8.4. INSTRUMENTS

9. BIOLOGICS SAFETY TESTING MARKET, BY TEST

  • 9.1. INTRODUCTION
  • 9.2. ENDOTOXIN TESTS
  • 9.3. STERILITY TESTS
  • 9.4. CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS
  • 9.5. BIOBURDEN TESTS
  • 9.6. RESIDUAL HOST CONTAMINANT DETECTION TESTS
  • 9.7. ADVENTITIOUS AGENT DETECTION TESTS
  • 9.8. OTHER TESTS

10. BIOLOGICS SAFETY TESTING MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA (ROA)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. EXPANSIONS
    • 11.3.2. ACQUISITIONS
    • 11.3.3. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 11.3.4. NEW PRODUCT AND SERVICE LAUNCHES
    • 11.3.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 12.1. INTRODUCTION
  • 12.2. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • 12.3. LONZA GROUP
  • 12.4. SIGMA-ALDRICH CORPORATION
  • 12.5. SGS S.A.
  • 12.6. WUXI PHARMATECH (CAYMAN) INC.
  • 12.7. AVANCE BIOSCIENCES INC.
  • 12.8. BSL BIOSERVICE
  • 12.9. CYTOVANCE BIOLOGICS, INC.
  • 12.10. MERCK KGAA
  • 12.11. TOXIKON CORPORATION

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: BIOLOGICS SAFETY TESTING MARKET SUMMARY
  • TABLE 2: RAPID GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES IS PROPELLING THE GROWTH OF THE BIOLOGICS SAFETY TESTING MARKET
  • TABLE 3: HIGH DEGREE OF CONSOLIDATION ACTS AS AN ENTRY BARRIER FOR NEW ENTRANTS
  • TABLE 4: INCREASING PHARMACEUTICAL OUTSOURCING PAVES NEW GROWTH AVENUES FOR PLAYERS IN THE BIOLOGICS SAFETY TESTING MARKET
  • TABLE 5: STRINGENT REGULATORY FRAMEWORKS ARE MAJOR CHALLENGES FOR MARKET PLAYERS
  • TABLE 6: MARKET DEVELOPMENTS BETWEEN 2011 AND 2014
  • TABLE 7: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 8: BIOLOGICS SAFETY TESTING MARKET SIZE FOR VACCINES AND THERAPEUTICS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 9: BIOLOGICS SAFETY TESTING MARKET SIZE FOR BLOOD AND BLOOD PRODUCTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 10: BIOLOGICS SAFETY TESTING MARKET SIZE FOR CELLULAR AND GENE THERAPY PRODUCTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 11: BIOLOGICS SAFETY TESTING MARKET SIZE FOR TISSUE AND TISSUE PRODUCTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 12: BIOLOGICS SAFETY TESTING MARKET SIZE FOR STEM CELL PRODUCTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 13: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 14: BIOLOGICS SAFETY TESTING KITS AND REAGENTS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 15: NORTH AMERICA: BIOLOGICS SAFETY TESTING KITS AND REAGENTS MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 16: ASIA: BIOLOGICS SAFETY TESTING KITS AND REAGENTS MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 17: BIOLOGICS SAFETY TESTING SERVICES MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 18: NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 19: ASIA: BIOLOGICS SAFETY TESTING SERVICES MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 20: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 21: NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 22: ASIA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET SIZE, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 23: BIOLOGICS SAFETY TESTING MARKET, BY TEST, 2012-2019 (USD MILLION)
  • TABLE 24: BIOLOGICS SAFETY TESTING MARKET FOR ENDOTOXIN TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 25: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ENDOTOXIN TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 26: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR ENDOTOXIN TESTS, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 27: BIOLOGICS SAFETY TESTING MARKET FOR STERILITY TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 28: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR STERILITY TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 29: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR STERILITY TESTS, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 30: BIOLOGICS SAFETY TESTING MARKET FOR CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 31: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 32: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 33: BIOLOGICS SAFETY TESTING MARKET FOR BIOBURDEN TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 34: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BIOBURDEN TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 35: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR BIOBURDEN TESTS, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 36: BIOLOGICS SAFETY TESTING MARKET FOR RESIDUAL HOST CONTAMINANT DETECTION TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 37: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR RESIDUAL HOST CONTAMINANT DETECTION TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 38: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR RESIDUAL HOST CONTAMINANT DETECTION TESTS, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 39: BIOLOGICS SAFETY TESTING MARKET FOR ADVENTITIOUS AGENT DETECTION TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 40: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ADVENTITIOUS AGENT DETECTION TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 41: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR ADVENTITIOUS AGENT DETECTION TESTS, COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 42: BIOLOGICS SAFETY TESTING MARKET FOR OTHER TESTS, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 43: NORTH AMERICA: BIOLOGICS SAFETY TESTS MARKET FOR OTHER TESTS, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 44: ASIA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER TESTS, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 45: BIOLOGICS SAFETY TESTING MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 46: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY, 2012-2019 (USD MILLION)
  • TABLE 47: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 48: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 49: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST, 2012-2019 (USD MILLION)
  • TABLE 50: U.S.: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 51: U.S.: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 52: CANADA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 53: CANADA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 54: EUROPE: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 55: EUROPE: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 56: EUROPE: BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST, 2012-2019 (USD MILLION)
  • TABLE 57: ASIA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY COUNTRY/REGION, 2012-2019 (USD MILLION)
  • TABLE 58: ASIA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 59: ASIA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 60: ASIA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST, 2012-2019 (USD MILLION)
  • TABLE 61: CHINA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 62: CHINA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 63: JAPAN: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 64: JAPAN: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 65: INDIA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 66: INDIA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 67: ROA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 68: ROA: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 69: ROW: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2012-2019 (USD MILLION)
  • TABLE 70: ROW: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2012-2019 (USD MILLION)
  • TABLE 71: ROW: BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST, 2012-2019 (USD MILLION)
  • TABLE 72: EXPANSIONS, 2012-2015
  • TABLE 73: ACQUISITIONS, 2012-2015
  • TABLE 74: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012-2015
  • TABLE 75: NEW PRODUCT AND SERVICE LAUNCHES, 2012-2015
  • TABLE 76: OTHER DEVELOPMENTS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL BIOLOGICS SAFETY TESTING MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2014 VS. 2019 (USD MILLION)
  • FIGURE 8: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2014 VS. 2019 (USD MILLION)
  • FIGURE 9: BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST, 2014 VS. 2019 (USD MILLION)
  • FIGURE 10: BIOLOGICS SAFETY TESTING MARKET SIZE, BY REGION, 2014 VS. 2019 (USD MILLION)
  • FIGURE 11: NORTH AMERICA COMMANDED LARGEST SHARE IN 2014
  • FIGURE 12: INCREASE IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES WILL DRIVE MARKET GROWTH
  • FIGURE 13: KITS AND REAGENTS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2014
  • FIGURE 14: ASIAN MARKET TO EXPERIENCE FASTEST GROWTH IN THE FORECAST PERIOD (2014 TO 2019)
  • FIGURE 15: ASIA POISED FOR LUCRATIVE GROWTH DURING THE FORECAST PERIOD
  • FIGURE 16: BIOLOGICS SAFETY TESTING MARKET SEGMENTATION: BY APPLICATION
  • FIGURE 17: BIOLOGICS SAFETY TESTING MARKET SEGMENTATION: BY PRODUCT
  • FIGURE 18: BIOLOGICS SAFETY TESTING MARKET SEGMENTATION: BY TEST
  • FIGURE 19: GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES WILL DRIVE THE BIOLOGICS SAFETY TESTING MARKET
  • FIGURE 20: INCREASING NUMBER OF NEW DRUG LAUNCHES TO DRIVE THE BIOLOGICS SAFETY TESTING MARKET IN THE FORECAST PERIOD
  • FIGURE 21: HIGH CAPITAL INVESTMENTS TO RESTRICT THE ENTRY OF NEW PLAYERS
  • FIGURE 22: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  • FIGURE 23: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION
  • FIGURE 24: BIOLOGICS SAFETY TESTING MARKET SIZE, BY APPLICATION, 2014 (USD MILLION)
  • FIGURE 25: VACCINE AND THERAPEUTICS WILL BE THE FASTEST-GROWING APPLICATION SEGMENT IN THE FORECAST PERIOD
  • FIGURE 26: NORTH AMERICA DOMINATED THE BLOOD AND BLOOD PRODUCTS APPLICATION SEGMENT IN 2014
  • FIGURE 27: ASIA TO WITNESS HIGHEST GROWTH IN THE CELLULAR AND GENE THERAPY PRODUCTS APPLICATION SEGMENT IN THE FORECAST PERIOD
  • FIGURE 28: NORTH AMERICA TO COMMAND LARGEST SHARE OF THE TISSUE AND TISSUE PRODUCTS APPLICATION SEGMENT IN THE FORECAST PERIOD
  • FIGURE 29: ASIA TO WITNESS HIGHEST GROWTH IN THE STEM CELL PRODUCTS APPLICATION SEGMENT TILL 2019
  • FIGURE 30: BIOLOGICS SAFETY TESTING MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 31: BIOLOGICS SAFETY TESTING MARKET SIZE, BY PRODUCT, 2014 (USD MILLION)
  • FIGURE 32: NORTH AMERICA DOMINATED THE BIOLOGICS SAFETY TESTING KITS AND REAGENTS MARKET IN 2014
  • FIGURE 33: U.S. DOMINATED THE BIOLOGICS SAFETY TESTING KITS AND REAGENTS MARKET IN NORTH AMERICA IN 2014
  • FIGURE 34: CHINA TO DOMINATED THE BIOLOGICS SAFETY TESTING KITS AND REAGENTS MARKET IN ASIA IN 2014
  • FIGURE 35: ASIA TO WITNESS THE HIGHEST GROWTH IN THE BIOLOGICS SAFETY TESTING SERVICES MARKET IN THE FORECAST PERIOD
  • FIGURE 36: U.S. TO DOMINATED THE BIOLOGICS SAFETY TESTING SERVICES MARKET IN NORTH AMERICA IN 2014
  • FIGURE 37: CHINA TO DOMINATE THE BIOLOGICS SAFETY TESTING SERVICES MARKET IN ASIA
  • FIGURE 38: NORTH AMERICA TO DOMINATE THE BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET IN THE FORECAST PERIOD
  • FIGURE 39: U.S. TO DOMINATED THE BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET IN NORTH AMERICA IN 2014
  • FIGURE 40: CHINA TO DOMINATE THE BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET IN ASIA IN THE FORECAST PERIOD
  • FIGURE 41: BIOLOGICS SAFETY TESTING MARKET, BY TEST
  • FIGURE 42: BIOLOGICS SAFETY TESTING MARKET SIZE, BY TEST, 2014-2019 (USD MILLION)
  • FIGURE 43: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE ENDOTOXIN TESTS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 44: THE U.S. TO ACCOUNT FOR THE LARGEST SHARE IN THE ENDOTOXIN TESTS SEGMENT IN NORTH AMERICA IN 2019
  • FIGURE 45: CHINA TO ACCOUNT FOR THE LARGEST SHARE IN THE ENDOTOXIN TESTS MARKET IN ASIA DURING THE FORECAST PERIOD
  • FIGURE 46: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE IN THE STERILITY TESTS SEGMENT IN 2019
  • FIGURE 47: THE U.S. TO ACCOUNT FOR THE LARGEST SHARE OF THE STERILITY TESTS SEGMENT IN NORTH AMERICA IN 2019
  • FIGURE 48: CHINA ACCOUNTED FOR THE LARGEST SHARE IN THE STERILITY TESTS SEGMENT IN ASIA IN 2014
  • FIGURE 49: NORTH AMERICA WILL ACCOUNT FOR THE LARGEST SHARE IN THE CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS SEGMENT IN 2019
  • FIGURE 50: THE U.S. TO ACCOUNTED FOR THE LARGEST SHARE OF THE CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS SEGMENT IN NORTH AMERICA IN 2014
  • FIGURE 51: CHINA ACCOUNTED FOR THE LARGEST SHARE IN THE CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS SEGMENT IN ASIA IN 2014
  • FIGURE 52: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE IN THE BIOBURDEN TESTS SEGMENT IN 2014
  • FIGURE 53: THE U.S. ACCOUNTED FOR THE LARGEST SHARE IN THE BIOBURDEN TESTS SEGMENT IN NORTH AMERICA IN 2014
  • FIGURE 54: CHINA ACCOUNTED FOR THE LARGEST SHARE IN THE BIOBURDEN TESTS SEGMENT IN ASIA IN2014
  • FIGURE 55: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE RESIDUAL HOST CONTAMINANT DETECTION TESTS SEGMENT IN 2014
  • FIGURE 56: THE U.S. TO ACCOUNT FOR THE LARGEST SHARE IN THE RESIDUAL HOST CONTAMINANT DETECTION TESTS SEGMENT IN NORTH AMERICA DURING THE FORECAST PERIOD
  • FIGURE 57: CHINA TO ACCOUNT FOR THE LARGEST SHARE IN THE RESIDUAL HOST CONTAMINANT DETECTION TESTS SEGMENT IN ASIA DURING THE FORECAST PERIOD
  • FIGURE 58: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE IN THE ADVENTITIOUS AGENT DETECTION TESTS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 59: THE U.S. TO ACCOUNT FOR THE LARGEST SHARE IN THE ADVENTITIOUS AGENT DETECTION TESTS SEGMENT IN NORTH AMERICA DURING THE FORECAST PERIOD
  • FIGURE 60: CHINA TO ACCOUNT FOR THE LARGEST SHARE IN THE ADVENTITIOUS AGENT DETECTION TESTS SEGMENT IN ASIA DURING THE FORECAST PERIOD
  • FIGURE 61: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE IN THE OTHER TESTS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 62: THE U.S. TO ACCOUNT FOR THE LARGEST SHARE IN THE OTHER TESTS SEGMENT IN NORTH AMERICA DURING THE FORECAST PERIOD
  • FIGURE 63: CHINA TO ACCOUNT FOR THE LARGEST SHARE IN THE OTHER TESTS SEGMENT IN ASIA DURING THE FORECAST PERIOD
  • FIGURE 64: BIOLOGICS SAFETY TESTING MARKET SEGMENTATION, BY REGION
  • FIGURE 65: BIOLOGICS SAFETY TESTING MARKET SIZE, BY REGION (MARKET SIZE AND GROWTH RATE), 2014-2019
  • FIGURE 66: ASIAN MARKET FOR BIOLOGICS SAFETY TESTING EXPECTED TO GROW AT THE HIGHEST RATE FROM 2014 TO 2019
  • FIGURE 67: U.S. COMMANDS THE LARGEST SHARE OF THE NORTH AMERICAN BIOLOGICS SAFETY TESTING MARKET IN THE FORECASTED PERIOD
  • FIGURE 68: NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY REGION (MARKET SIZE AND GROWTH RATE), 2014-2019
  • FIGURE 69: KITS AND REAGENTS HELD THE LARGEST SHARE OF THE BIOLOGICS SAFETY TESTING MARKET IN NORTH AMERICA IN 2014
  • FIGURE 70: VACCINES AND THERAPEUTICS FORMED THE LARGEST APPLICATION SEGMENT IN NORTH AMERICA IN 2014
  • FIGURE 71: ENDOTOXIN TESTS FORMED THE LARGEST TEST SEGMENT IN NORTH AMERICA IN 2014
  • FIGURE 72: KITS AND REAGENTS FORMED THE LARGEST PRODUCT SEGMENT IN THE U.S. IN 2014
  • FIGURE 73: VACCINES AND THERAPEUTICS APPLICATION SEGMENT HELD THE LARGEST SHARE IN THE U.S. MARKET DURING THE FORECAST PERIOD
  • FIGURE 74: KITS AND REAGENTS HELD THE LARGEST SHARE AMONG ALL PRODUCT SEGMENTS IN CANADA IN 2014
  • FIGURE 75: VACCINES AND THERAPEUTICS FORMED THE LARGEST APPLICATION SEGMENT IN CANADA IN 2014
  • FIGURE 76: KITS AND REAGENTS HELD THE LARGEST SHARE OF THE BIOLOGICS SAFETY TESTING PRODUCTS MARKET IN EUROPE IN 2014
  • FIGURE 77: VACCINES AND THERAPEUTICS FORMED THE LARGEST APPLICATION SEGMENT IN EUROPE IN 2014
  • FIGURE 78: ENDOTOXIN TESTS ACCOUNTED FOR THE LARGEST SHARE OF BIOLOGICS SAFETY TESTING MARKET IN 2014
  • FIGURE 79: CHINA COMMANDS THE LARGEST SHARE OF THE ASIAN BIOLOGICS SAFETY TESTING MARKET DURING THE FORECAST PERIOD
  • FIGURE 80: ASIA: BIOLOGICS SAFETY TESTING MARKET, BY REGION (MARKET SIZE AND GROWTH RATE)
  • FIGURE 81: KITS AND REAGENTS PRODUCT SEGMENT DOMINATED ASIAN BIOLOGICS SAFETY TESTING MARKET IN 2014
  • FIGURE 82: VACCINES AND THERAPEUTICS APPLICATION SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIAN BIOLOGICS SAFETY TESTING MARKET IN 2014
  • FIGURE 83: ENDOTOXIN TESTS ACCOUNTED FOR THE LARGEST SHARE OF THE BIOLOGICS SAFETY TESTING MARKET IN ASIA IN 2014
  • FIGURE 84: KITS AND REAGENTS WERE THE LARGEST PRODUCT SEGMENT IN CHINA IN 2014
  • FIGURE 85: VACCINES AND THERAPEUTICS HELD THE LARGEST SHARE OF THE CHINESE MARKET IN 2014
  • FIGURE 86: KITS AND REAGENTS FORMED THE LARGEST PRODUCT SEGMENT IN JAPAN IN 2014
  • FIGURE 87: VACCINES AND THERAPEUTICS APPLICATION SEGMENT HELD THE LARGEST SHARE OF THE JAPANESE MARKET IN 2014
  • FIGURE 88: KITS AND REAGENTS FORMED THE LARGEST AND FASTEST-GROWING PRODUCT SEGMENT IN INDIA IN 2014
  • FIGURE 89: VACCINES AND THERAPEUTICS FORMED THE LARGEST AND THE FASTEST-GROWING APPLICATION SEGMENT IN INDIA IN 2014
  • FIGURE 90: KITS AND REAGENTS COMMANDED THE LARGEST SHARE OF THE ROA BIOLOGICS SAFETY TESTING MARKET IN 2014
  • FIGURE 91: VACCINES AND THERAPEUTICS APPLICATION SEGMENT DOMINATES ROA MARKET IN 2014
  • FIGURE 92: KITS AND REAGENTS COMMANDED THE LARGEST SHARE OF THE ROW BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT
  • FIGURE 93: VACCINES AND THERAPEUTICS WERE THE LARGEST APPLICATION SEGMENT IN 2014
  • FIGURE 94: ENDOTOXIN TESTS SEGMENT DOMINATES ROW MARKET IN 2014
  • FIGURE 95: EXPANSIONS AND ACQUISITIONS ARE THE KEY STRATEGIES ADOPTED BY PLAYERS
  • FIGURE 96: BIOLOGICS SAFETY TESTING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
  • FIGURE 97: BATTLE FOR MARKET SHARE: EXPANSIONS AND ACQUISITIONS WERE THE KEY STRATEGIES
  • FIGURE 98: MARKET EVOLUTION FRAMEWORK: EXPANSION AND ACQUISITION HAVE AIDED MARKET GROWTH
  • FIGURE 99: SNAPSHOT FOR THE FINANCIAL PERFORMANCES OF THE LEADING MARKET PLAYERS
  • FIGURE 100: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 101: LONZA GROUP: COMPANY SNAPSHOT
  • FIGURE 102: SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
  • FIGURE 103: SGS SA: COMPANY SNAPSHOT
  • FIGURE 104: WUXI PHARMATECH (CAYMAN) INC.: COMPANY SNAPSHOT
  • FIGURE 105: MERCK KGAA: COMPANY SNAPSHOT
Back to Top